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The design of particulate vaccine delivery systems, particularly for mucosal surfaces, has been a focus of interest in recent years. In this context, we
have previously described the development and the characterization of a new nanosized delivery system, consisting of a model antigen adsorbed to
chitosan particles and coated with sodium alginate. In the present work the ovalbumin release profiles from these coated nanoparticles in different pH
buffers were investigated and compared to those of the uncoated particles. Cytotoxicity of the polymers and nanoparticles was assessed using the MTT
assay. Finally, particle uptake studies in rat Peyer's patches were performed. It was demonstrated that the coating of the nanoparticles with sodium
alginate not only avoided a burst release observed with uncoated particles but also increased the stability of the particles at pH 6.8 and 7.4 at 37 °C. At
neutral pH, the release was lower than 5% after 3.5 h incubation in a low ionic strength buffer. For both, chitosan and alginate polymers, and for the
nanoparticles, comparable cell viability data close to 100%, were obtained. Additionally, based on confocal laser scanning microscopy observations, it
was shown that alginate coated nanoparticles were able to be taken up by rat Peyer's patches, rendering them suitable carriers for intestinal mucosal
vaccination.
© 2006 Elsevier B.V. All rights reserved.Keywords: Coated nanoparticles; Chitosan; Sodium alginate; Peyer's patches; Cytotoxicity1. Introduction
The primary reason for using the mucosal route of vaccination
is that it is the most effective route to induce a local protective
immune response, resulting in the release of sIgA, against infec-
tions originating at a mucosal surfaces [1,2]. However, only few
vaccines currently approved for human use are administered
mucosally, most of which are live-attenuated ones. Mucosal vac-
cines, comprising soluble protein antigens, in general yielded
rather disappointing results. Many factors have been described⁎ Corresponding author. Tel.: +351 239859927; fax: +351 239827126.
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doi:10.1016/j.jconrel.2006.06.011causing this problem [2] and different strategies have been applied
to meet this challenge [2,3]. One such strategy is the development
of polymeric nanoparticulate delivery systems. In general, these
systems are thought to promote entrapment and retention of
antigens in local lymph nodes [4]. On the other hand, they might
protect the antigens from the adverse environment in the presence
of hydrolytic enzymes or low pH at the gastrointestinal mucosal
surface.
In a recent publication we have described the development and
the characterization of a new nanosized delivery system, consis-
ting of chitosan nanoparticles with ovalbumin adsorbed at the
surface and coated with sodium alginate [5]. These particles were
designed for crossing mucosal barriers and releasing the antigen
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the present manuscript, successive studies related to this new
delivery system are presented.
One of the objectives of the present study was to assess the
model vaccine release profiles from coated nanoparticles in order
to examine the nature of the interactions between the chitosan core
and the alginate coating. Furthermore, these studies were per-
formed to obtain information about the in vivo antigen released
from the particles.
The second objective was to evaluate the potential of these
coated particles for being taken up by Peyer's patches. Mucosal
uptake of microparticulates has been a matter of several reviews
[6,7]. Particularly, a number of studies, not only in rodent animal
models [8,9] but also in porcine gut [10] showed the uptake of
chitosan nanoparticles by Peyer's patches [8,9] or by gut villous
cells [10]. Likewise, studies using in vitro cell culture models
demonstrated the uptake of chitosan nanoparticles by a number of
different cell lines [9,11–15] and it was emphasised that the
polycationic, mucoadhesive chitosan nanoparticles revealed a
stronger association with mucus-secreting cells MTX-E12 than
with Caco-2 cell monolayers [9]. An intense electrostatic inter-
action between positively charged chitosan nanoparticles and
negatively charged mucins is regarded as the cause for the strong
interaction of chitosan with mucus [9,16]. In one of our own
recent studies the coating of the chitosan nanoparticles with
sodium alginate has inverted the surface charge of the particles
from positive to negative values [5], however, the hydrophilicity
of these mucoadhesive [17] nanoparticles remained unaltered.
The present coated nanoparticles presumably have the same sur-
face properties as alginate nanoparticles and recent studies [18–
20] have shown that alginate particles, despite of their negative
surface charge, are also able to be taken up by Peyer's patches.
Thus, we examined the internalization of these coated particles by
Peyer's patches.
Finally, the third objective was to evaluate the cytotoxicity of
the coated and uncoated nanoparticles in comparison to the
polymers used to prepare these particles. The in vitro evaluation
of the cytotoxicity of chitosan has been performed in a number of
previous studies [11,21–24] with different cell lines and its low
cytotoxicity has already been demonstrated. However, different
results were found in the literature, which may possibly be related
to the presence of impurities on the different sources of bulk
polymer. On the other hand, the differences observed can also be
associatedwith the concentration of the polymer in the cell culture
or to different incubation times of the polymer with the cells or
finally to the cell line used. For instance for A549 cells, a cell
viability near 100% (MTT assay) was demonstrated [11] with
concentrations lower than 0.74 mg/ml, and a mean IC50 value of
1.1 mg/ml and 1.2 mg/ml for chitosan and chitosan nanoparticles,
respectively. With Calu-3 cells a concentration of 1.5% of chito-
san in culture medium decreased the cell viability to 30% [23].
Similarly, sodium alginate has been widely used because of its
biodegradability, biocompatibility [25] and low toxicity [26].
Examples of its utilization include the immobilization of living
cells [27] and the production of antigen delivery systems [28].
The MTT assay is considered an easy and rapid test for the
evaluation of cytotoxicity and was used in this work to assess thecytotoxicity of the polymers, chitosan or sodium alginate and the
alginate coated or uncoated chitosan nanoparticles in mice spleen
cells.
2. Materials and methods
2.1. Materials
2.1.1. Polymers
Chitosan (ChitoClear™) was purchased from Primex Bio-
Chemicals AS (Avaldsnes, Norway). According to the provider's
specifications, the degree of deacetylation was 95% (titration
method) and the viscosity was 8 cP (measured in 1% solutions in
1% acetic acid). Sodium alginate (MANUCOL LB®) was kindly
donated by ISP Technologies Inc. (Surrey, UK).
2.1.2. Reagents
Ovalbumin (grade V; minimum 98%), [3-(4,5-dimethylthia-
zol-2-yl)] 2,5-diphenyl tetrazolium bromide (MTT), trypan blue
and concanavalin A (con A) were purchased from Sigma Che-
micals (St. Louis, USA), certified fetal bovine serum (fbs), L-
glutamine (200 mM) and gentamicin were from Gibco (Invitro-
gen Co., Paisley, Scotland, UK), 1 M HEPES buffer (0.85%
NaCl) and RPMI 1640 without L-glutamine were from Biowhi-
taker (Cambrex Bio Science, Verviers, Belgium), ovalbumin
fluorescein conjugate (3.9 mol dye/mole protein) and BODIPY®
665/676 from Molecular Probes (Leiden, The Netherlands). All
other reagents used were of analytical grade. All solutions were
prepared in Millipore water.
2.2. Preparation of alginate coated chitosan nanoparticles
Alginate coated chitosan nanoparticles were prepared by the
method described previously [5]. Chitosan was dissolved at a
concentration of 0.25% (w/v) in an acetic acid solution and the
formation of the particles was achieved after the addition of 3.5ml
of sodium sulfate solution (10% w/v) to 200 ml of the chitosan
solution. The resultant suspension of particles was centrifuged for
30 min at 3500 rpm (2800×g) and the supernatant was discarded.
The particles were suspended in Millipore water and centrifuged
twice more and then were frozen in liquid nitrogen and freeze-
dried overnight using a Christ freeze-dryer (Osterode am Harz,
Germany). The dry powder was kept frozen until further use.
The loading with ovalbumin was performed by incubating a
solution of ovalbuminwith a suspension of chitosan particles at pH
7.4 (phosphate buffer) under mild agitation at room temperature
during 120 min. The resulting suspension of 0.25% (w/v) oval-
bumin and 0.4% (w/v) nanoparticles was used in successive
release studies as uncoated loaded nanoparticles and was used in
the subsequent coating step. Alginate coated nanoparticles were
obtained by mixing of equal volumes of nanoparticles suspension
and a buffer phosphate solution of sodium alginate (1%w/v) under
magnetic stirring. The agitation was maintained during a 20 min
period. The suspension was then centrifuged for 10 min at
1600 rpm and the supernatant was discarded. The particles were
re-suspended in 0.524 mM CaCl2 in 50 mM HEPES buffer
solution and kept under agitation for another 10 min.
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Ovalbumin release from the coated and uncoated particles was
performed by incubation in several buffers: 8 mM phosphate
buffer pH 7.4, 100 mM phosphate buffer pH 5.5, 5 mM HEPES
buffer pH 7.4, simulated intestinal fluid (SIF) and in simulated
gastric fluid (SGF), as described in USP XXIV. The nanoparticle
suspensions were added (1:4) to individual tubes containing the
release medium previously equilibrated at 37 °C and placed in a
shaker bath adjusted to 50 rpm. At appropriate time intervals,
samples were taken from each tube and filtered through a low
protein-binding filter (MILLEX®GV — 0.22 μm; Durapore
PVDFmembrane; MILLIPORE, Molsheim, France) followed by
centrifugation for 20 min at 14,000 rpm. The concentration of
ovalbumin in the supernatant was assayed by BCA-protein assay.
Simultaneously coated and uncoated blank (without ovalbumin)
nanoparticle suspensions were subjected to the same conditions
and the filtered samples were used as blanks in the BCA-protein
assay. For the determination of the total protein content in the
particle suspension, 0.5 ml of the suspensions of the coated and
uncoated particles were incubated with 1.5 ml of 0.085 N hydro-
chloric acid solution (pH=1.2) in an ultrasound bath for 30 min,
followed by 3 h in awater bath at 37 °C. The samples were filtered
and the protein was assayed by BCA-protein assay. Suspensions
of unloaded particles were analysed under the same conditions
and were used as a blank for the correction of the OD value of the
samples analyzed with BCA-protein assay. In order to calculate
the amount of the ovalbumin encapsulated, the concentration of
unbound ovalbumin in the supernatant of particle suspensions
was also determined and subtracted from the total concentration
of the ovalbumin in suspension. All experiments were performed
at least in triplicate.
The data of ovalbumin release from the coated nanoparticles in
the phosphate buffers at different pHs (5.5, 6.8 and 7.4), were
analyzed according to zero-order kinetics, first-order kinetics,
Higuchi, Korsmeyer-Peppas, Hopfenberg andWeibull as described
in [29]. All kinetic models were fit to the release date (graphMt/M0
versus time) using the SigmaPlot software (version 8.0, SPSS Inc.)
The drug loading capacity (LC) and loading efficacy (LE) of
the nanoparticles were calculated using the following equations:
LC ðw=wÞ ¼ ðtotal amount of ovalbumin − non
 bound ovalbuminÞ=weight of the
nanoparticles
ð1Þ
LE ð%Þ ¼ ðtotal amount of ovalbumin non
 bound ovalbuminÞ=total amount of ovalbumin
⁎100 ð2Þ2.4. Cytotoxicity studies
2.4.1. Preparation of single cell suspensions of spleen cells
Three 8-week old female BALB/c mice (Harlan Iberica,
Barcelona, Spain) were sacrificed by cervical dislocation and their
spleens were aseptically removed. Individual spleen cell suspen-
sions were prepared in a Petri dish using curved needles and
washed twice with RPMI 1640. The final suspension was
adjusted to a final concentration of 1×107 cells perml in completeRPMI 1640 medium (supplemented with 10% (v/v) fetal bovine
serum, 1% (v/v) glutamine, 1% (v/v) gentamicin and 2% (v/v)
1 M HEPES buffer).
2.4.2. Solutions of the polymers
The 0.25% chitosan test solution was prepared with complete
RPMI and the 0.25% sodium alginate was prepared in 50 mM
HEPES buffer (pH=7.4). The solutionswere heated and sonicated
in order to completely dissolve the polymers. Immediately prior to
incubation with the cells, the solutions were aseptically filtered.
2.4.3. In vitro stimulation of spleen cells with polymer solutions
and nanoparticle suspensions and MTT assay
Using sterile 96-well tissue culture plates (TPP, Switzerland),
25 μl of splenocyte suspension from three mice were plated
individually, in triplicate along with 20 μl of a concanavalin A
solution (50 μg/ml in complete RPMI solution) and 135 μl of a
complete RPMI solution of the polymer or suspension of the
nanoparticles and incubated (95% relative humidity, 5% CO2) for
20 h. Assayed were 138.8 μg/ml and 208.3 μg/ml of the polymers
(chitosan and sodium alginate), respectively, and 277.6 μg/ml and
416.6μg/ml of the coated and uncoated nanoparticles, respectively.
The solvents used for the preparation of the polymer solutions
(see Section 2.4.2) were also assayed as a control of the experiment.
In the sameway, the solutions of the polymers and the suspension of
the particles were assayedwithout cells in order to evaluate possible
interferences of the polymers or the particles in the MTT assay.
Cytotoxicity was evaluated by measuring the reduction of
MTT by the mitochondrial dehydrogenase of living cells as an
indication of cell viability. 18 μl of MTT solution (5 mg/ml in a
phosphate buffered saline pH 7.4) were added to each well
following 2.5 h of additional incubation at 37 °C. To ensure
solubilization of the formazan crystals, 100 μl of 0.1 N isopro-
panol–HCl was added to each well and the optical density values
were measured at 570 nm using a microplate reader. The relative
cell viability (%) related to control wells containing spleen cells in
culture medium without polymer was calculated by equation:
% cell viability ¼ ½A test=½A control 100 ð3Þ
In order to analyse and compare the results for the control
group with the polymer and nanoparticle groups, a one-way
ANOVA analysis followed by Dunnett's post test was performed
using the GraphPad Prism 4 software. Significant differences
were considered for p<0.05.2.4.4. Trypan blue and propidium iodide stain
The viability of the splenocytes was also evaluated by the
capability of these cells with uncompromised membrane integrity
to exclude the dye. The in vitro stimulation of the cells with the
polymers or the nanoparticles was done as described above in the
absence of concanavalinA and for a period of 15 h. Three samples
of the same animal weremixedwith a PBS solution of trypan blue
and the resultant suspensions (0.2% trypan blue) were visualized
using a standard light microscope. Stained and unstained cells
were counted manually using a hemocytometer. Additionally, the
pooled culture cells from the same animal and the same
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(0.25 μg/ml) and the fluorescence immediately measured with a
fluorescence activated cell sorter (FACS Calibur) (BD, Bios-
ciences, Madrid, Spain). Data were analysed by Cell Quest
software (BD, Biosciences, Madrid, Spain).
Data were presented as means±S.E.M. for three experiments
and statistical significance was assessed using repeated measured
one-way ANOVA followed by Dunnett's post test using the
GraphPad Prism 4 software. Significant differences were consi-
dered for p<0.05.
2.5. Uptake studies in rat Peyer's patches
The studies with Wistar rats (Charles River, Someren, The
Netherlands) were performed according to the guidelines of the
Ethical Committee of Leiden University. Male rats weighing
250–340 g were housed for acclimatization one week before the
experiments with free access to food and water with 12 h light/
dark cycle. On the day before the experiment they were starved
overnight, allowing only free access to water.
The rats were anaesthetized by IM administration of 0.5 ml/kg
of Hypnorm® (fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/
ml) and 0.5 ml/kg of Dormicum® (midazolam 5 mg/ml). The
animals remained anaesthetized throughout the experiment and
were placed on electrical heatingmats.A small incision in the lower
stomach was made and a teflon tube (∅: 0.5 mm I.D.×1.0 mm O.
D.) was introduced through the pylorus approximately 3 to 5 cm
into the duodenum. The coated particle suspensions loaded with
FITC–ovalbumin or the 0.05% FITC–ovalbumin PBS solutions
were administered (500 μl) and the incision was closed after the
removal of the tube from the stomach. The rats were sacrificed after
2 h by cervical dislocation. The whole intestine was removed and
flushed with 20 ml of phosphate buffered saline. Between 4 and 5
Peyer's patcheswere excised from each intestine and fixedwith 2%
paraformaldehyde, rinsed again with PBS (4 °C) and the tissue was
permeabilized by immersion in 0.1% Triton X-100 (PBS) for
20 min. The tissue was rinsed again and stained with a 0.0617%
solution of BODIPY® 665/676 (Pierce, Leiden, The Netherlands)
in methanol for 60 min. Finally, the Peyer's patches were mounted
on glass slides and observed using a confocal laser scanning
microscope (CLSM) (Bio-Rad, Alphen a/d Rijn, The Netherlands).
The confocal images were obtained by scanning the tissue samples
in the x, y plane with a z-step of 500 nm.
Fluorescein label (FITC) coated nanoparticles were prepared
according to the procedure described above, using a 0.05%
FITC–ovalbumin solution in phosphate buffered saline.
Three rats for the group control (solution of the FITC–
ovalbumin) and four rats for the group treated with the suspension
of the FITC-coated nanoparticles were included in this study.
3. Results and discussion
3.1. Characterization of the nanoparticles
In a recent publication [5] of our group, the development of
alginate coated chitosan nanoparticles was described and the
characterization of this new delivery system reported. Beforecoating with sodium alginate, chitosan nanoparticles had a mean
diameter of 643 nm (dynamic light scattering technique) and were
positively charged (+37 mV). Scanning electron microscopy
(SEM) images of uncoated particles also revealed the presence of
small nanoparticles (around 100 nm). After the coating process,
however, SEM micrographs allowed us to verify that most of the
particles were in a range between 300 and 600 nm. The presence of
the alginate coating layer was confirmed by FTIR and DSC studies
and by the observation of the inversion of the zeta potential
(−34mV) of coated nanoparticles. The loading of the nanoparticles
was done by an adsorption process based on electrostatic
interaction [30–32] between the negatively charged ovalbumin at
pH 7.4 and the positively charged chitosan nanoparticles. The
excellent properties of the chitosan delivery systems to adsorb at its
surface proteins [33,34] and vaccines [30,35], renders them a
promising carrier systems. In the present work, the ovalbumin
loading efficacy (see Eq. (2)) of uncoated particles prepared under
the conditions described before was 75%, and the loading capacity
(see Eq. (1))was 0.49mgovalbumin/mg of nanoparticleswhich are
close to those results found in literature [34]. Smaller values of
those quantities, of loading efficacy and loading capacity, 57% and
0.39 mg ovalb./mg particles respectively, were observed for the
alginate coated particles.
Moreover, physical degradation, including aggregation of
the ovalbumin, released from the coated nanoparticles, was not
observed as was previously demonstrated by SDS-PAGE [5].
This result was not a surprise because the ovalbumin loading
process, as well as the following step, the coating of the nano-
particles with sodium alginate, were performed using a
phosphate buffer (pH 7.4), considered as mild entrapment
process, having no deleterious effect on the conformation of the
protein [36].
3.2. In vitro release studies
3.2.1. Ovalbumin release profiles from chitosan nanoparticles
In vitro release studies in various aqueous media were per-
formed in order to evaluate the differences of ovalbumin release
profiles from uncoated and coated nanoparticles and as an attempt
to understand the physicochemical structure of these two delivery
systems. The results are illustrated in Fig. 1 for the uncoated
chitosan nanoparticles and in Fig. 2 for the alginate coated chito-
san nanoparticles.
An almost complete ovalbumin desorption from uncoated
particles was observed immediately after the addition of the
suspension of the particles to the equilibrated release medium at
pH 1.2 (simulated gastric fluid) and pH 5.5 (100 mM buffer
phosphate). At low pH values, chitosan nanoparticles displayed
probably the highest positive surface charge due to the proto-
nation of the free amine groups of chitosan. Additionally, oval-
bumin has also predominantly positive charges below its
isoelectric point (ovalbumin isoforms: pI between 4.8 and 5.0)
[37], resulting from the protonation of the amine group. The
combination of these two factors can explain the immediate
desorption of ovalbumin. Such behaviour, the burst release, also
allowed us to suggest that ovalbumin was mostly adsorbed to the
surface of the particles and not inside the pores.
Fig. 1. In vitro release profiles of ovalbumin from uncoated chitosan nanoparticles
into various aqueous dissolution media at 37 °C. Mean±standard deviation, n=3.
352 O. Borges et al. / Journal of Controlled Release 114 (2006) 348–358On the other hand, when the release studies of uncoated
particles were conducted at pH 7.4 (phosphate buffer), the initial
white colour of the nanoparticle suspension disappeared, imme-
diately after its addition to the release medium, reappearing, in a
progressive way after a few seconds. This phenomenon was
believed to be related to the destruction of the initial structure of
the nanoparticles as a consequence of its instability at 37 °C in
phosphate buffer (pH 7.4), followed by the formation of new
nanoparticles (precipitates), indicated by turbidity [32] examined
by transmission measurements at 500 nm (data non shown). As a
consequence, in the first moment after the addition of the particles
suspension to the release medium, an immediate desorption of the
ovalbumin from the particles occurred, to which followed a
progressive re-association of the protein to the recently formed
particles and the establishment of a new adsorption equilibrium.
This new equilibrium was then stable, under the given conditions
of buffer strength and pH. This occurrence was reflected by the
atypical release profile shown in Fig. 1. Similar results were
observed when the study was repeated at 37 °C with HEPES
buffer (pH 7.4) (Fig. 1). Once the ovalbumin loading of the
particles was conducted with the same buffer (phosphate buffer)
at room temperature, it was assumed that the observed inter-
mediate instability of the particles was probably related, not only
to the pH of the release medium, but also to the temperature.
Furthermore, the small size of the particles is also an important
factor contributing to the instability of the delivery system and
consequently to the initial fast release [38] of ovalbumin. This
instability was also described in our own previous studies [5] in
simulated intestinal fluid (SIF). However, this behaviour was not
observed by others which could mean that despite of the appa-
rently similar formulation and preparation procedures, a diversity
of characteristics of the chitosan particles exist [33,34,39–43].
The cause of different release behaviours from chitosan nano-
particles may be related with its process of preparation. Recently,the importance of controlling the pH of the formulation during
chitosan nanoparticles preparation was demonstrated [14]. Other
parameters, such as deacetylation degree and molecular weight of
the polymer also has an impact on the properties of the final
nanoparticles [33]. Nevertheless, it should be emphasised that a
correct procedure during the release studies must be followed,
including the rigorous verification of the temperature of the
release medium, 37 °C, before the start of the experiment.
3.2.2. Ovalbumin release profiles from alginate coated chitosan
nanoparticles
In contrast to uncoated chitosan nanoparticles, the release
profile of ovalbumin from nanoparticles was significantly
modified after coating with sodium alginate (Fig. 2a). In a pH
7.4 (phosphate buffer) more than 40% of the ovalbumin was
released within the first 60 min and during the following 16 h not
more than an additional 25% was released. On the other hand,
when usingHEPES buffer of the same pHor plainwater, notmore
than 5.8% of the ovalbumin was released within the first 3 h and
only 4% of ovalbumin was released in water after 17.5 h from the
alginate-coated particles. The observed differences at the same
pH, are believed to be related, not only to the ionic strength of the
buffers used, but also to the composition of the buffer. The high
affinity of phosphate ions to the calcium ions is well known.
Therefore, when pH phosphate buffers are used, the destabilizing
of calcium-crosslinked alginate matrix has to be taken into ac-
count. This effect may cause a faster opening or breakdown of
crosslinking compared to the results in HEPES buffer or to plain
water where this reaction does not occur. The loss of the calcium
ions from the alginate coating, has as a consequence, the increase
of the permeability of the coating and consequently an increased
diffusion of the ovalbumin into the release medium. Furthermore,
the highest ionic strength of the phosphate buffer, compared with
HEPES buffer and water should have an important impact on the
weakening of the interactions, between the chitosan core and the
alginate coating. This dependence on the ionic strength (pH 7.4) is
typical of electrostatic interaction, and consequently these obser-
vations reinforce our previous considerations about the electro-
static nature of the interactions between the alginate coating and
the chitosan core [5].
Finally, when the ovalbumin release study was conducted
using a pH 5.5 phosphate buffer, the differences observed when
compared to the same phosphate buffer of pH 7.4, should be
attributed to the pH of the buffer. The pH (5.5) seemed to be
favourable to maintain strong interactions between alginate and
chitosan and this was probably the cause for the maintenance of
the entrapment of ovalbumin at an elevated percentage. A com-
parable result was observed (Fig. 2a) at pH 6.8 in SIF.
As evident from what was referred before, the release of
ovalbumin from the coated particles is actually a result of a
combination of different processes which made the application of
a kinetic model a difficult task [38]. In particular, the electrostatic
interactions between the chitosan core and the ovalbumin should
have a determinant role in the release mechanism and should be
impeditive to observe a good fit with a diffusion-controlled re-
lease mechanism. In fact among several models referred,
including the ones of Higuchi, Korsmeyer-Peppas, Hopfenberg
Fig. 2. (a) In vitro release profiles of ovalbumin from alginate coated chitosan nanoparticles into various aqueous dissolution media at 37 °C. Mean±standard deviation,
n=3. (b, c and d) Release-time profile (Mt /M0 versus time) from alginate coated particles up to 180 min with the first order mass balance function.Mt /Mo is the fraction of
drug release after time t.
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studies performed in the phosphate buffers at different pHs (5.5,
6.8 and 7.4), showed to have the best fit for the first order model
(Fig. 2b,c,d), described by following equation:
Mt=M0 ¼ a⁎½1−expð−btÞ ð4Þ
Where Mt /M0 is the fraction of drug released at time t. The
two parameters of Eq. (4), the pre-exponential term a and the
first-order constant b were estimated by this fitting process and
their values are shown in Fig. 2b,c,d. The first-order model
release mechanism has been associated with particular char-
acteristics of the delivery system; they reflected to some extent a
reservoir-type delivery system [44]. Moreover, it was suggested
that the first order kinetics could describe the release profile,
from the pharmaceutical dosage forms such as those containing
water-soluble drugs (that is the case of ovalbumin in the present
study), where drugs would be released at the rates proportional
to the amounts of drug remaining inside the dosage form [45].
Similar to our results, it was demonstrated in a recent study
[46], that the 5-Flu release data, from both liposomes and PLGAor PLA microspheres, were modelled as a first-order process,
with excellent reproducibility of the release kinetics.
The alginate coating of the nanoparticles not only improved the
stability of the chitosan particles at 37 °C in 6.8 and 7.4 pH buffers,
but also allowed a significant reduction of the ovalbumin burst
release observed for the uncoated particleswith the different buffers,
with an exception at pH 1.2 (SGF). The release characteristics of the
present nanoparticles may be altered by the increase in complexity
(presence of surfactants, enzymes, salts) of the selected release
buffer. Thus in order to obtain a better knowledge of the situation in
vivo, more complete in vitro models would be required.
3.3. In vitro cell viability studies
Splenocytes have been used for the evaluation of the toxico-
logical profiles of several compounds and delivery systems. For
example, in a recent study, the evaluation of the cytotoxicity of
tetanus toxoid loaded poly(lactide-co-glycolide) nanospheres was
done with splenocytes [47]. The principal reason for the choice of
spleen cells in this study, was related to the fact that they are
obtained and cultured easier, compared to other lymphoid organs,
Fig. 4. Viability of splenocytes measured by the reduction of MTT. The cells were
incubated for 20 h in the presence of two different concentrations of the nano-
particles, alginate coated chitosan particles and uncoated chitosan particles. The
control group corresponds to the assay just with cells in culture medium. Results
represent themean±standard error of themean for 3 differentmice, eachperform in
triplicate (n=9). Statistical difference between control group and formulations are
reported as: ⁎p<0.05, ⁎⁎p<0.01. Cell viability (% of the control)=[A] test / [A]
control×100.
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representative of the different cells of mucosal immune system.
The spleen is a lymphoid organ, bridging the innate and adaptive
immune system in a uniquely organized way (reviewed in Ref.
[48]). A primary culture of mixed spleen cells normally contains
(FACS analysis performed in our own lab) more than 50% of B
lymphocytes, about 30% of T lymphocytes (18% CD4+; 12%
CD8+) and less than 20% erythrocytes, fibroblast, macrophages,
dendritic cells, and granulocytes. Similar to the spleen, Peyer's
patches also contain a large number of B cells, T cells, macro-
phages and dendritic cells [15]. Thus, a primary culture of spleen
cells should have the requisites to mimic possible toxic effects of
the nanoparticles, when the nanoparticles, internalized by Peyer's
patches, remain in a close contact with those immune cells during
a certain period of time.
In this study, the viability of primary culture of splenocytes in
the presence of the polymers sodium alginate and chitosan, at two
different concentrations, was evaluated by different methods, and
in order to estimate whether the preparation process of the par-
ticles would introduce any cytotoxicity, uncoated and alginate
coated chitosan particles were also studied.
The MTT test was used to evaluate the effects of the polymers
and the particles on the metabolic activity of mice spleen cells. No
evidence of cytotoxicity was observed for the polymer solutions
(Fig. 3) or the particle suspensions (Fig. 4) and a cell viability of
around 100% was observed in all test groups. Moreover, the
statistical analysis of the results underlined the higher mean
values of cell viability (% of control) in the groups treated with
higher concentrations of polymers, chitosan or alginate and with
particles coated or uncoated (in both concentrations) when com-
pared with the control group. Considering that proliferating cells
are metabolically more active than non-proliferating (resting)
cells, these results can also be interpreted as the possible impact of
polymers and particles on cell proliferation. This is probably an
indication that the polymers may favourably influence lysosomalFig. 3. Viability of splenocytes measured by the reduction of MTT. The cells were
incubated for 20 h in the presence of two different concentrations of polymers,
chitosan and sodium alginate. The control group corresponds to the assay just with
cells in culturemedium. Results represent themean±standard error of themean for
3 different mice, each performed in triplicate (n=9). Statistical differences between
control group and formulations are reported as: ⁎p<0.05, ⁎⁎p<0.01. Cell viability
(% of the control)=[A] test / [A] control×100.and mitochondrial activity of the cells [22], nevertheless, this
observation needs to be confirmed by specific experiments.
On the other hand, the cytotoxicity results as measured by the
reduction of the MTT substrate could, in theory, be “masked” by
cellular proliferation. Therefore, it was decided to conduct
cytotoxicity studies with a different methodology using trypan
blue or propidium iodide (PI) dyes for staining the cells whose
membrane integrity may have been compromised. The results of
this study are summarized in Figs. 5, 6, and 7. The count of non-
viable splenocytes stained with trypan blue (Fig. 5) in comparison
with the non-stained cells revealed that the presence of the
polymers during 15 h did not decrease the percentage of viable
cells and are in close agreement with the results obtained from the
MTT assay. FACS sorting and analysis (Fig. 6) of lymphocytes
previously treatedwith PI strengthened these observations and the
proportion of dead (M1) cells in all the samples was always lower
than 3%. The statistical analysis of these results showed that the
values obtained in each treatment group were not different from
the control group. However, a more pronounced difference bet-
ween the location of FL3 histograms from control groups (Fig. 7,
left and right picture) and groups treated with a solution of the
polymers chitosan or sodium alginate (Fig. 7, right picture) was
observed. These results possibly indicate that in the presence of
the polymers, a slight perturbation of the plasma membrane
occurred and these lymphocytes are more permeable to the fluo-
rescent nuclear probe, PI. Nevertheless, this event did not induce
cell death, as was demonstrated by trypan blue dye exclusion and
MTTassays. The present results correlate with those found in the
literature [21] where it was demonstrated that chitosan increased
the Caco-2 cell permeability in a reversible and dose-dependent
way and was not accompanied by cell extrusion.
The combination of these three different methods adds reli-
ability to the final evaluation of the cytotoxicity profiles of these
polymers and nanoparticulate formulations.
Fig. 5. The viability of splenocytes measured by counting trypan blue stained and
unstained cells with hemocytometer. The cells were incubated for 15 h in the
presence of two different concentrations of the polymers, chitosan and sodium
alginate. The control group corresponds to the assay just with cells in culture
medium. Results represent the mean±standard error of the mean for 3 different
mice (n=3) and each count was the result of pooled samples from the same mice.
No statistical differences were found between the control and the polymer groups.
Fig. 6. Flow-cytometric analysis of mice splenocytes previously incubated in the
presence of two different concentrations of the polymers chitosan and sodium
alginate during 15 h. The FL3 histograms show the proportion of PI stained non-
viable (M1) and viable cells from pooled samples of one mouse. Each histogram
is representative of three animals studied individually. No statistical significant
differences were found when the control group was compared with the other
treatment groups.
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into rat Peyer's patches after intra-duodenal administration
The uptake of alginate coated chitosan nanoparticles into the
rat Peyer's patches through M-cells was investigated. Chitosan
particles were loaded with ovalbumin labelled with fluorescein as
a model vaccine and then coated with sodium alginate. To better
visualise the contour of the cells, the Peyer's patches were stained
with Bodipy®, which is a nonpolar lipophilic dye used to stain the
cell membrane. The same methodology was recently used suc-
cessfully to visualise the uptake of N-trimethyl chitosan nano-
particles by nasal epithelia and NALT cells [49] or to visualize
chitosan nanoparticles within Peyer's patches [8]. In the present
work, CLSM images of Peyer's patches from the rats treated with
the suspension of fluorescent coated nanoparticles, showed the
presence of fluorescent nanoparticles (green spots) inside the
Peyer's patch (upper pictures in Fig. 8). The nanoparticles were
visualized, not only in the region underneath (0.5 μm) the follicle-
associated epithelium (FAE) (right upper picture in Fig. 8), the
subepithelial dome region (SED), but also in deeper regions of the
secondary lymphoid organ (left upper picture in Fig. 8). Z-scan
images (21 images), in successive steps (0.5 μm distance between
steps) and starting 67 μm deep from the surface of the Peyer
patches, also indicated that the nanoparticles were also trans-
ported to deeper regions (data not shown). On the contrary, the
photos from the control group (lower pictures in Fig. 8), treated
with a solution of ovalbumin–FITC did not show any green
fluorescence except a slight shade green (lower left picture) that
could mean that a small amount of ovalbumin–FITC could be
absorbed by the tissue.
Some of the green dots visualized in the Peyer's patches
seemed not to be individual particles, but agglomerates of the
nanoparticles taken up into lysosomal compartments. Focusing of
sections at high power suggested that microparticle clusters were
localised intracellularly (left upper picture in Fig. 8), an obser-
vation consistent with a recently published study [50] in which
CLSM images were presented, showing clusters of polystyrene
nanoparticles present in the subepithelial dome region underlying
the Peyer's patch. Moreover, in the same study, dendritic cellslabelled by immunostainingwere shown to efficiently phagocytose
microparticles and when the microparticles were associated to
enterotoxin adjuvants, they were transported from the SED region
into underlying B-cell follicles and adjacent parafollicular T-cell
zones.
The SED region underlying the FAE are rich in phagocytic
cells (dendritic cells and macrophages) [50]. Recent published
studies, showed that alginate nanoparticles are able to be taken up
not only in vivo by Peyer's patches [18–20], but also in vitro by
phagocytic cells [19,51]. Following this idea, alginate coated
chitosan nanoparticles were most likely internalized by phago-
cytic cells, most probably dendritic cells, present in Peyer's
patches. In future work it will be important to determine the
phenotype and maturation state of the microparticle-loaded cells
as it can be important to follow and to know the mechanism of
phagocytic cells migration.
As an important finding, this study provided an answer to our
initial question related to the capability of this new delivery
system, formed by hydrophilic negatively charged particles, to be
internalized by Peyer's patches. In spite of the argument that
Fig. 7. Flow-cytometric FL3 histogramoverlay of control groups on the left picture
and control plus polymer treatment (sodium alginate and chitosan) on the right
picture.
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due to its better interaction with lipophilic cell membranes, this
study showed that also negatively charged hydrophilic particles
are being internalised. Moreover in a recent study [51], the
increase of the hydrophobicity of alginate particle surface did not
improve its uptake by mouse macrophages and consequently,
cellular uptake seems to be the result of a complex combination ofFig. 8. CLSM visualization of rat Peyer's patches (PP). Upper images belong to the
nanoparticles. Left image was taken from the transversal cross section of the intestinal
epithelial barrier. In all the PP from the intestine of the four rats, treated with the na
different from the three animals fed with FITC–ovalbumin in the PBS solution. Righsize, hydrophobicity, as well as specific interactions between
surface functional groups of alginate microspheres and the cell
membrane.
4. Conclusions
The adsorption of therapeutic proteins and model antigens
onto chitosan nanoparticles has proven to be a very mild process
resulting in a very high loading efficacy. In this study, it was
shown that coating of this delivery system with sodium alginate
yielded coated particles, in the nanosize range, with a much better
stability and controlled release properties for vaccine delivery,
than the chitosan loaded cores themselves. It was also demons-
trated that the preparation process of the nanoparticles did not
introduce any toxic compound on the particles. On the contrary, a
slight stimulation of the splenocytes co-cultured with the nano-
particles was observed. Finally it was shown that these hydro-
philic coated nanoparticles even with a negative surface charge
were taken up by rat Peyer's patches, whichmade thempromising
carriers for mucosal vaccination. In vivo studies with a real
vaccine are underway to investigate the efficacy of this new
mucosal delivery system.different animal treated with FITC–ovalbumin loaded alginate coated chitosan
epithelial barrier and the right image was taken from the villi side of the intestinal
noparticles, similar CLSM images could be made. Lower images belong to two
t and left images were taken from the villi side of the intestinal epithelial barrier.
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